Pipradrol

Pipradrol

Clinical data
ATC code	N06BX15 (WHO)
Legal status
Legal status	Class C (UK/NZ)
Identifiers
IUPAC name α,α-Diphenyl-2-piperidinemethanol
CAS Number	46-76-07
E number	{{#property:P628}}
ECHA InfoCard	{{#property:P2566}}
Chemical and physical data
Formula	C18H21NO
Molar mass	267.37

WikiDoc Resources for Pipradrol
Articles
Most recent articles on Pipradrol Most cited articles on Pipradrol Review articles on Pipradrol Articles on Pipradrol in N Eng J Med, Lancet, BMJ
Media
Powerpoint slides on Pipradrol Images of Pipradrol Photos of Pipradrol Podcasts & MP3s on Pipradrol Videos on Pipradrol
Evidence Based Medicine
Cochrane Collaboration on Pipradrol Bandolier on Pipradrol TRIP on Pipradrol
Clinical Trials
Ongoing Trials on Pipradrol at Clinical Trials.gov Trial results on Pipradrol Clinical Trials on Pipradrol at Google
Guidelines / Policies / Govt
US National Guidelines Clearinghouse on Pipradrol NICE Guidance on Pipradrol NHS PRODIGY Guidance FDA on Pipradrol CDC on Pipradrol
Books
Books on Pipradrol
News
Pipradrol in the news Be alerted to news on Pipradrol News trends on Pipradrol
Commentary
Blogs on Pipradrol
Definitions
Definitions of Pipradrol
Patient Resources / Community
Patient resources on Pipradrol Discussion groups on Pipradrol Patient Handouts on Pipradrol Directions to Hospitals Treating Pipradrol Risk calculators and risk factors for Pipradrol
Healthcare Provider Resources
Symptoms of Pipradrol Causes & Risk Factors for Pipradrol Diagnostic studies for Pipradrol Treatment of Pipradrol
Continuing Medical Education (CME)
CME Programs on Pipradrol
International
Pipradrol en Espanol Pipradrol en Francais
Business
Pipradrol in the Marketplace Patents on Pipradrol
Experimental / Informatics
List of terms related to Pipradrol

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]

Overview

Pipradrol (Meretran) is a mild central nervous system stimulant that is no longer widely used in most countries due to concerns about its abuse potential, although this is less of a problem than with other stimulants that still are in current use such as methylphenidate. Pipradrol is still used in some European countries, and even rarely in the USA.

Pipradrol was developed in the 1950s and found use initially for treating obesity. It was subsequently used for the treatment of a variety of other conditions such as narcolepsy, ADHD, and most particularly for counteracting the symptoms of senile dementia, this being the only application for which it is still used medically. Pipradrol proved useful for these applications as its relatively mild stimulant effects gave it a good safety profile compared to stronger stimulants. It was also trialled as an adjutant treatment for depression and schizophrenia although it was never widely used for these purposes.

Pipradrol was made illegal in many countries in the late 1970s, at the same time as many other drugs which had a history of abuse. The relatively mild stimulant effects of pipradrol meant that it was scheduled under the less restrictive classes in most countries (i.e. Class C in United Kingdom and New Zealand) but was still considered of sufficient abuse potential to be made an illegal drug. It is now an obscure compound that is virtually unknown as an illicit drug of abuse, but is still used for some scientific research, often as a comparison drug for testing other stimulants against.

Dosage is between 0.5 and 4 milligrams per day, typically taken as a single dose in the morning as the long duration of effects of pipradrol (up to 12 hours) means insomnia can be a problem especially if it is used at higher doses or taken too late in the day.

Common side effects include insomnia, anorexia, tachycardia, anxiety. Rarer side effects include dry mouth, tremor, hypertension, euphoria, depression, and very rarely psychosis or convulsions.